when was glp-1 discovered Discovery of GLP-1–Based Drugs for the Treatment of Obesity The Story of GLP-1: A
Description
The legal framework that made mass-market compounded GLP-1s widely available was built on FDA shortage designations for branded semaglutide and tirzepatide
You searched
With diabetes diagnoses significantly increasing and obesity rates skyrocketing, there is a growing demand for effective treatments that manage blood sugar levels and promote weight loss
That is lower than many tirzepatide starting dose protocols
Blood Sugar Effects Both medications improve glucose metabolism: Liraglutide: HbA1c reduction of 0.5-1.0% at weight loss doses Originally developed for diabetes (Victoza) Modest glucose benefits at Saxenda doses Semaglutide: HbA1c reduction of 1.0-1.8% at diabetes doses Greater glucose improvement than liraglutide Significant benefit for prediabetes and diabetes For patients with diabetes or prediabetes, semaglutide provides greater metabolic benefit
107 Interestingly, only an estimated 15% of the active GLP-1 reaches the portal vein before the liver, due to the rapid inactivation through DPP-IV
